Balancing the scales
Besides the balanced reasoning within the Delhi HC judgement, it is the SC's intervention which could see this case go down as a…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Category
Editor’s note
Mainstreaming AYUSH
The last month saw a major milestone in the patent versus patient debate
Playing for high stakes
According to the latest data from the India Brand Equity Foundation (IBEF), the Indian domestic pharma market ended FY15 with a…
Mylan’s One Quality Standard a long way off
Some industry observers are surprised that ‘significant violations’ of this nature have not warranted an import alert or ban
New strategies for growth
After a decade of pain, there are some reassuring signs that the pharmaceutical industry may just be seeing the faint glimmers of…
Digital India: A new game needs new rules
With the launch of the Digital India campaign in early July, it is time to relook India Pharma Inc’s engagement with technology
Lee Pharma revives the CL debate
With little known Lee Pharma filing India's third compulsory licensing (CL), legal eagles and everyone interested or connected to…
TRIPs-ing time again
When governments have to weigh public health against IP issues, LDCs and developing countries really have no choice but to plug…
Data integrity … dil se
Two reports, released in early June, have both good news and bad news for the pharma industry in India
Wish list for PM Modi’s second year
Just as 2015 is a make or break year for PM Modi, this will be a decisive year for the pharma sector as well Now that the…
When patience is not a virtue
India once again made it to the Priority Watch list of the 2015 USTR Special 301 Report, but this year, the reaction from India’s…
Rebooting Jan Aushadhi
As Prime Minister Modi completes a year in office this May, there will no doubt be many lists of this government’s achievements…
Good growth prospects despite headwinds
As we settle into FY2016, it is worth taking a quick look at some of the earning previews of the last quarter
Making hay while the Sun shines
Success hinges on the company getting its GMP right and surviving the glare of regulatory scrutiny
Intent right, but implementation is key
Finance Minister Arun Jaitley’s first Union Budget had nothing special for the pharmaceutical industry
Policy pinings
As in previous years, we mark this Women's Day with a cover story section devoted to women's health issue
The politics of IPR policy
The draft National IPR policy, unveiled last December by the Department of Industrial Policy & Promotion (DIPP), has already…
The bigger picture vs the nitty-gritty
While we are urged to look beyond the sticky issues, one cannot overlook the final impact of decisions on India's IPR policy
Could a surgeon become DCG(I)?
CDSCO's planned 'harmonisation of recruitment rules' is sure to resurrect this debate